My take is that compounding pharmacies are once again eating into LLY’s market share by dint of the FDA’s rescinding its order for the compounders to stop making Tirzepatide.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”